Clinical Trial Update: A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety of concurrent durvalumab with concomitant radiotherapy and consolidation durvalumab in Chinese patients with unresectable Stage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Unresectable Stage III NSCLC | Phase 2 | Status: UNKNOWN